GCM
ALNY icon

Greenland Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Greenland Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,959
Closed -$893K – 329
2025
Q3 		$893K Buy
1,959
+959
+96% +$391K 0.09% 171
2025
Q2 		$326K Hold
1,000
– – 0.03% 279
2025
Q1 		$270K Sell
1,000
-1,000
-50% -$257K 0.03% 258
2024
Q4 		$471K Buy
2,000
+896
+81% +$236K 0.08% 207
2024
Q3 		$304K Buy
+1,104
New +$287K 0.04% 273

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Greenland Capital Management's ALNY Position: Q4 2025 in Review

Greenland Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2025, closing a stake of 1,959 shares — an estimated $893K sold.

Greenland Capital Management first reported a position in ALNY in Q3 2024 and held it in 5 quarters. The position peaked at $893K in Q3 2025. 848 funds tracked by Wall St. Rank hold ALNY as of Q4 2025.

  • Greenland Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Greenland Capital Management sold 1,959 Alnylam Pharmaceuticals shares in Q4 2025, an estimated $893K.
  • Greenland Capital Management first reported a position in Alnylam Pharmaceuticals in Q3 2024 and held it in 5 quarters.
  • Greenland Capital Management's Alnylam Pharmaceuticals position peaked at $893K in Q3 2025.
  • 848 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2025.

Based on Greenland Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.